##
##
|Mr
I C Martin|||Chair||||||
|---|---|---|---|---|---|---|---|---|
|Dr D G Mason|||Honorary|Treasurer|(Demitted||10w November|2022)|
|Associate Professor||PI Greaves|Honorary|Treasurer|||||
|Mrs 1 Barber|||||||||
|Professor Ti|Hendra||Demitted|10u November||2022|||
|Professor Sir|8Keogh||||||||
|Professor
N Kumar|||||||||
|Dr 5 Ushman|CBE||||||||
|Professor M Sani|||||||||
|The Trust|ees|have ma|de the following
professional
appointments:||
|---|---|---|---|---|
|Solicitor;|||H Montlake
&Co, 198High Street, llford, Essex IG11'||
|Auditor:|||Kreston Reeves, Montague
Place, Quayside,
Chatham
Maritime,
Chatham,
ME4 4QU||
|Bankers:|||CAF Bank Limited, 25 Kings Hill Avenue,
Kings Hill, West Mailing, Kent ME1941Q||
||||CCLA Investment
Management
Limited, 80Cheapside,
London
EC2V 6DZ||
||||Virgin Money, iubilee House, Gosforth, Newcastle
upon Tyne, NE34PL||
||||'The Charity Bank Umited,
Fosse House, 182High Street, Tonbrldge,
TN9 1BE||
||||Nationwide
Building Society, Nationwide
I-louse, Pipers Way, Swindon,
SN38 1NW||
|Stockbrokers:|||Quilter Cheviot Investment
Management,
Senator House, 85 Queen Victoria St, London|EC4V|
||||4AB||
|Insurance|Brokers:||Insurance
Services (Surrey) Ltd, PO Box1533,Woking, GU22 2RY||
||||Secondslght,
Foster Denovo Group, 2 Hamm Moor lane, Weybridge,
Surrey KT15 2SA||
|The following||key senior members ofstaff are responsible
for the day-to-day
activities ofthe charity who together||with|
|the Trustees||form the|key management
personnel ofthe charity:||
##
##
##
##
|Association ofAnaesthetlsts|||||Royal College|ofNursing|||
|---|---|---|---|---|---|---|---|---|
|Dr W Fawcett|||||Dr N Ashby||||
|Association ofSurgeons of Great Britain||and|Ireland||Royal College|ofObstetricians|and Gynaecologists||
|Mr M Lansdown|||||Dr T Hillard||||
|Royal College ofEmergency Medicine|||||Royal College|of Paedlatrics and Child||Health|
|Dr A Boyle -demltted
10'"November|2022||||Drl Doughty||||
|Katherine Henderson-appointed
10u November||||2022|||||
|Faculty ofDental Surgery|||||Royal College|ofPhysicians ofLondon|||
|Mri Dhanda
Faculty ofIntensive
Care Medicine '|||||Dr A Gibson,
Royal College|Dr M Kumwenda
ofPsychiatrists|and Dr|H Skene|
|DrI Butler —demltted
20u June 2022|||||DrJohnathan|Richardson —appointed||10u November|
|Dr Dhruv Parek —appointed 31"January 2023|||||2022||||
|Lay Representatives|||||Royal College|ofRadiologlsts|||
|Vacancy|||||Prof R McWilliams||||
|Royal College ofAnaesthetists|||||Royal College|ofPathologists|||
|Dr C Carey|||||Dr L Igall —demltted
28'"April||2022||
|Dr K Ramachandaran
—demitted
28u|April 2022||||||||
|Dr Barbara Bahlmann —appointed
1(F"November||||2022|||||
|Dr Subash Siv-appointed
10u November||2022|||||||
|Royal College of General Practitioners|||||Royal College|ofSurgeons ofEngland|||
|DrCatherine
Mllllngton-Sanders
—appointed|||10u||Miss 5Vlg||||
|November
2022|||||||||
##
|Coroners' Society of England and Wales|Dr DSharpstone|
|---|---|
|Healthcare
Quality Improvement
Partnership|Mr M Skrypak|
|Healthcare
Quality Improvement
Partnership|Mr D Smith|
|Healthcare
Quality Improvement
Partnership|Mrs V Dunne|
|Royal College of Physicians
and Surgeons ofGlasgow|Dr G Curry|
|Royal College of Physicians of Edinburgh|Dr J MacLeod|
|Royal College ofSurgeons of Edinburgh|Miss A Paisley|
|Dr|A Goodwin|Anaesthesia
and Critical Care|
|---|---|---|
|Dr|M Juniper|Respiratory
Medicine|
|Dr|K Malbon|Paediatrics|
|Dr|S McPherson|Radiology|
|Dr|D McWilllams|Physiotherapy|
|Dr|A Michalskl|Paediatric Oncology|
|Mr|M Sinclair|General Surgery|
|Dr|VSrivastava|Acute Medicine|
|Dr|A Tavare|General Practice|
|Mr|IAberuombie|Colorectal Surgery|
##
##
##
##
##
##
##
##
|1.Form the Study Advisory|Group (SAG)|6.Advertise for reviewers|||11.Run reviewer meetings|
|---|---|---|---|---|---|
|2.Undertake
su
/focus|rou|7.Test data cogectlon methods|||12.Data ana
sls|
|3.Write the
rotocol||8.Meet with the SAG fora second|time||13.Write the re ort|
|4. Desi
n the
uestlonnaires||9.Final protocol toSteering Grou|and|HQIP|14.De
n the re ort|
|S.Advertise the stud||10.Start data collection|||16.Pubgsh the re on|
##
##
##
##
##
##
##
|Area ofstudy:|||||Milestone reached:||
|---|---|---|---|---|---|---|
|Transition
between||chgd||and adult healthcare|Due for publication|BuJune 23|
|Crohn's disease|||||Due for publication|lge July 23|
|Commun
ac|aired||neumonia||Data being analysed||
|Testicular torsion|||||Data collection underwa||
|Endometriosis|||||Data collection underway||
|End of life care|||||Data collection underway||
|Natural deaths|In|risen|||Data collection underwa||
|Juvenile arthritis|||||Data collection underway||
|Rehabilitation|following|||critical illness|Stu
being develo|ed|
|Blood sodium|||||Stu
bein
develo|ed|
|New 1|||||To be chosen||
|New 2|||||To be chosen||
|New 3|||||To be chosen||
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
|||Total|Total|
|---|---|---|---|
||Notes|2023|2022|
|||E|E|
|INCOME FROM:||||
|Donations||202,320|132,900|
|Charitable
activities||1,242,245|1,243,871|
|Investments||15,367|6,741|
|TOTAL INCOME||1,459,932|1,383,512|
|EXPENDITURE ON:||||
|Charitable
activities||1,443,417|1,216,165|
|TOTAL EXPENDITURE||1,443,417|1,216,165|
|Net loss/ gain on investments||(19,051)|11,311|
|NET EXPENDITURE / INCOME||(2,536)|178,658|
|NET MOVEMENT
IN FUNDS||(2,536)|178,658|
|RECONCILIATION
OF FUNDS||||
|Fund balances brought forward||||
|at 1April 2022||1,694,229|1,515,571|
|FUND BALANCES CARRIED FORWARD||||
|AT31MARCH 2023||1,691,692|1,694,229|
##
|||Notes|2023|2022|
|---|---|---|---|---|
||||E|6|
|FIXED ASSETS|||||
|Tangible assets|||7,530|838|
|Investments|||204,798|223,849|
||||212,328|224,687|
|CURRENT ASSETS|||||
|Debtors|||366,213|376,339|
|Cash at bank and ln|hand||1,174,480|1,264,869|
||||1,540,693|1,641,208|
|LIABILITIES|||||
|Creditors: Amounts|falling due within one year|10|(31,329)|(171,666)|
|NET CURRENT ASSETS|||1,509,364|1,469,542|
|TOTAL ASSETS LESS|CURRENT LIABILITIES||1,721,692|1,694+29|
|Provisions for liabilities|||(30,000)||
|TOTAL NET ASSETS|||1,691,692|1,694,229|
|THE FUNDS OF THE|CHARITY||||
|Unrestricted
Income funds|||||
|GeneralFund|||1,691,692|1,664,229|
|Designated
Premises|Fund|||30,000|
|TOTAL CHARITY FUNDS|||1,691,692|1,694,229|
##
|||||Notes|2023|2022|
|---|---|---|---|---|---|---|
||||||E|E|
|Cash flows from ope rating|activities||||||
|Net cash provided
by operating||activities||13|(96,119)|167,023|
|Cash flows from Investing|activities||||||
|Interest from Investments|||||15,367|6,741|
|Purchase oftangible Rxed|assets||||(9,637)|(504)|
|Receipts from sale ofinvestments|||||||
|Purchase ofinvestments|||||||
|Net cash (outflow) inflow|from investing||activities||3,730|6,237|
|Increase (decrease) ln cash for the year|||||(90,389)|173,260|
|Cash brought forward|||||1,264,869|1,091,609|
|Cash canted forward|||||||
||||||1,174,480|1,264,869|
##
##
##
##
##
##
##
##
##
##
##
##
##
##
##
||||Total|Total|
|---|---|---|---|---|
||||2023|2022|
||||6|6|
|1.|DONATIONS:||||
||Donated services||202,320|132„E}00|
||||202,320|132300|
||INCOME FROM CHARITABLE ACTIVITIES —DESIGNING AND RUNNING||CONFIDENTIAL SURVEY||
||Healthcare
Quality Improvement||1,205,122|1,207,221|
||Partnership
(HQIP)||||
||Private hospitals||31,000|30,650|
||Conference,
exhibition|and other|||
||income sources||6,123|6,000|
||||1,242,245|1,243,871|
||INVESTMENT INCOME||||
||Dividends||6,752|6,079|
||Bank interest receivable|on|||
||short term cash deposits||8,615|662|
||||15,367|6,741|
##
|||||Total|Total|
|---|---|---|---|---|---|
|||||2023|2022|
|||||E|E|
|Support costs (note 5)||||304,090|241369|
|Direct staff costs (note 6)||||658,335|574,354|
|Other direct expenditure:||||||
|Staff healthcare,
training,|and recruitment|||2,083|2,337|
|Clinical co-ordinators
secondments||||161,092|217,746|
|Clinical reviewers
(donated services)||||202,320|132,900|
|Clinical co-ordinators,
reviewers,||and||||
|staff expenses||||52,574|14,757|
|Consultancy||||2,476|13,235|
|Temporary
staff costs||||35,632|4,696|
|Conference, exhibition,
and meetings||||||
|expenses||||7,618|371|
|Operating
lease rentals:||||||
|Plant and machinery||||2,863|7,247|
|Other printing
and report|production||costs|7,361|4,782|
|Postage and distribution||||7,666|2,371|
|||||1,443,417|1,216,165|
|||Support|Governance|Total|Total|
|---|---|---|---|---|---|
|||costs|costs|2023|2022|
|||E|6|E|E|
|SUPPORT AND GOVERNANCE|COSTS|||||
|Staff costs (note 6)|||873|873|746|
|Otherexpendlture:||||||
|Operating
lease rentals:||||||
|Land and buildings||141,437||141,437|133,644|
|Other premises costs||28,218||28,218|22,521|
|Auditors'
remuneration:||||||
|Audit fees|||8,774|8,774|8,100|
|Bookkeeping and payroll costs||9,700|14|9,714|9,366|
|Public relations||-60||-60|860|
|Computer
expenses||27,127|38|27,165|21,951|
|Insurance||24,142|34|24,176|20,592|
|Sundry expenses||5,338|8|5,346|6,065|
|Telephone||4,627|7|4,634|4,748|
|Office costs||17,674|25|17,699|8,947|
|Steering Group expenses||1,378|4|1,383|681|
|Trustee expenses||1,708||1,708||
|Depredation
-owned assets||2,941||2,945|2,958|
|Bank charges||79||79|190|
|Dilapidation
provisions||30,000||30,000||
|||294,309|9,781|304,090|241,369|
|PRIOR|YEAR COMPARATIVE||||||
|---|---|---|---|---|---|---|
||||Support|Governance|Total|Total|
||||costs|costs|2022|2021|
||||E|E|6|6|
||SUPPORT AND GOVERNANCE|COSTS|||||
||Staff costs (note 6)|||746|746|691|
||Other expenditure:||||||
||Operating
lease rentals:||||||
||Land and buildings||133,644||133,644|136,747|
||Other premises costs||22,521||22,521|15,854|
||Auditors'
remuneration:||||||
||Audit fees|||8,100|8,100|10,288|
||Bookkeeping and payroll costs||9,352|14|9,366|11,086|
||Public relations||859|1|860|454|
||Computer
expenses||21,919|32|21,951|31,127|
||Insurance||20,562|30|20,592|17,635|
||Sundry expenses||6,054|11|6,065|4,247|
||Telephone||4,741|7|4,748|4,536|
||Office costs||8,933|14|8,947|5,400|
||Steering Group||680|1|681||
||Trustee expenses||||||
||Depreciation
—owned assets||2,954|4|2,958|5,934|
||Bank charges||190||190|143|
||||232,410|8,959|241,369|244,142|
##
|||||2023|2022|
|---|---|---|---|---|---|
|STAFF COSTS||||||
|||||No.|No.|
|The average monthly
number ofpersons employed|||by|||
|NCEPOD during the year (exduding|Trustees) was:|||||
|Designing
and running ofconRdentlal||surveys||16|14|
|Staff costs for the above persons:||||||
|Wages and salaries||||544,319|480526|
|Social security costs||||62,246|47,322|
|Pension costs||||51,770|47,252|
|||||658,335|575,100|
|Staff costs are allocated
In the financial||statements,|as follows:|||
|Designing
and running ofconRdentlal||surveys —unrestricted||657,642|574354|
|Governance
costs||||873|746|
|||||658,335|575,100|
##
||||Computer|Fixtures &||
|---|---|---|---|---|---|
||||equipment|fittings|TOTAL|
||||E|E|E|
|Cost:||||||
|1April 2022|||17,112|15,033|32,145|
|Additions|||2,024|7,613|9,637|
|Disposals||||(15,034)|(15,034)|
|31March 2022|||19,136|7,612|26,748|
|Depreciation:||||||
|1Aprll2022|||16,274|15,033|31,308|
|Charge
ln the year|||1,422|1,523|2,945|
|Depreciation
on disposal||||(15,034)|(15,034)|
|31March 2023|||17,696|1,522|(19,218)|
|Net book value:||||||
|31March 2023|||1,440|6,090|7,530|
|31March 2022|||838||838|
|||||2023|2022|
|INVESTMENTS||||||
|Usted investments:||||||
|Opening
balance at 1April||||223,849|212,538|
|Additions at cost||||||
|(inc cash account movement)||||||
|Dlsposals||||||
|Realised gains/losses|In|investments||||
|Unreallsed
losses/gains||on Investments||(19,051)|11,311|
|Market value at 31March||||204,798|223,849|
##
##
|||||2023|2022|
|---|---|---|---|---|---|
||Analysis ofinvestment|holdings||||
||QC Global income and|Growth|Fund|204,798|223,849|
||Market value at31March|||204,798|223,849|
||DEBTORS|||||
||Amounts
falgng due within one||year:|||
||Trade debtors|||290,439|304,871|
||Other debtors|||24,643|24,643|
||Prepayments|||51,131|46,825|
|||||366,213|376339|
|10.|CREDITORS|||||
||Amounts
falling due within one||year.|||
||Trade creditors|||6,862|7,752|
||Accruals and deferred|income||24,467|163,914|
|||||31,328|171,666|
||Deferred income|||||
||Deferred Income at 1April 2022|||110,000|88,000|
||Resources deferred
during the year||||22,000|
||Amounts
released from previous years|||(110,000)||
||||||110,000|
##
##
##
|||1April|Income|Expenditure|Loss on|Transfers|31March|
|---|---|---|---|---|---|---|---|
|||2022|||Investment||2023|
|||E||E|E||E|
|Unrestricted||Income funds:||||||
|General|Fund|1,664,229|1,459,932|(1,443,417)|(19,051)|30,000|1,691,692|
|Designated||30,000||||(30,000)||
|Premises|Fund|||||||
|||1,694,229|1,459,932|(1,443,417)|(9,051)||1,691,692|
|||1April|Income|Expenditure|Loss on|Transfer|31March|
|---|---|---|---|---|---|---|---|
|||2021|||Investment||2022|
|||E||E|E|||
|Unrestricted||Income funds:||||||
|General|Fund|1,495,571|1,383,512|(1,216,165)|11,311|(10,000)|1,664,229|
|Designated||20,000||||10,000|30,000|
|Premises|Fund|||||||
|||1,515,571|1,383,512|(1,216,165)|11,311|1,710,424|1,694,229|
##
||||Fixed asset|Tangible fixed|Net current|Total|
|---|---|---|---|---|---|---|
||||Investments|assets|assets||
||||6|E|E||
|Unrestricted|income|funds:|||||
|General
Fund|||204,798|7,530|1,479,364|1,691,692|
|Designated|Premises|Fund|||||
|NET ASSETS|AT31MARCH 2023||204,798|7,530|1,479,364|1,691,692|
||||Fixed asset|Tangible fixed|Net current|Total|
||||investments|assets|assets||
||||E|6|E||
|Unrestricted|income|funds:|||||
|General
Fund|||223,849|838|1,439,542|1,664,229|
|Designated|Premises|Fund|||30,000|30,000|
|NET ASSETS|AT31MARCH 2022||223,849|838|1,469,542|1,694,229|
##
||||2023|2022|
|---|---|---|---|---|
||||E|E|
|Net Income forthe|year||(2,536)|178,659|
|Depreciation
(note|7)||2,945|2959|
|Loss on Investments|||19,051|(11,311)|
|Interest from Investment|||(15,367)|(6,741)|
|Decrease (Increase)|In debtors||10,126|(20,582)|
|(Decrease) increase|in creditors||(110337)|24,039|
|Net cash from operating||activities|(96,119)|167,023|
##
|||2023||2022||
|---|---|---|---|---|---|
|||land & Building|Equipment|Land & Building|Equipment|
|Within|1year|6144,904|E5,606|E69,323|E5,606|
|Within|2-5 years|217,356|E15,418||622,424|
|Total||6362360|E21,024|E69,323|628,030|
|15.|NET DEBTRECONCIUATION||||
|---|---|---|---|---|
|||At1April 2022|Cash flows|At31March 2023|
|||E|E|E|
||Cash at bank and in hand|1,264,869|(90,389)|1,174,480|
||Debt||||
||Total|1,264,869|(90,389)|1,174,480|
|16.|ANALYSIS OF CASH AND CASH|EQUIVALENTS|||
|||2023|2022||
|||E|E||
||Cash ln hand|1,174,480|1,264,869||
||Total cash and cash equivalents|1,174,480|1,264,869||
##